These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 18276619)

  • 1. Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial.
    Montalescot G; Cohen M; Salette G; Desmet WJ; Macaya C; Aylward PE; Steg PG; White HD; Gallo R; Steinhubl SR;
    Eur Heart J; 2008 Feb; 29(4):462-71. PubMed ID: 18276619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial.
    White HD; Gallo R; Cohen M; Steg PG; Aylward PE; Bode C; Steinhubl S; Montalescot G
    Am Heart J; 2009 Jan; 157(1):125-31. PubMed ID: 19081408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.
    Montalescot G; White HD; Gallo R; Cohen M; Steg PG; Aylward PE; Bode C; Chiariello M; King SB; Harrington RA; Desmet WJ; Macaya C; Steinhubl SR;
    N Engl J Med; 2006 Sep; 355(10):1006-17. PubMed ID: 16957147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial.
    Mehta SR; Steg PG; Granger CB; Bassand JP; Faxon DP; Weitz JI; Afzal R; Rush B; Peters RJ; Natarajan MK; Velianou JL; Goodhart DM; Labinaz M; Tanguay JF; Fox KA; Yusuf S;
    Circulation; 2005 Mar; 111(11):1390-7. PubMed ID: 15781750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of anticoagulation regimens on sheath management and bleeding in patients undergoing elective percutaneous coronary intervention in the STEEPLE trial.
    Gallo R; Steinhubl SR; White HD; Montalescot G;
    Catheter Cardiovasc Interv; 2009 Feb; 73(3):319-25. PubMed ID: 19213086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention.
    Chen WH; Lau CP; Lau YK; Ng W; Lee PY; Yu CM; Ma E
    J Invasive Cardiol; 2002 Aug; 14(8):439-42. PubMed ID: 12147872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
    Montalescot G; Collet JP; Tanguy ML; Ankri A; Payot L; Dumaine R; Choussat R; Beygui F; Gallois V; Thomas D
    Circulation; 2004 Jul; 110(4):392-8. PubMed ID: 15249498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?
    Henry TD; Satran D; Knox LL; Iacarella CL; Laxson DD; Antman EM
    Am Heart J; 2001 Oct; 142(4):590-3. PubMed ID: 11579347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematomas of at least 5 cm and outcomes in patients undergoing elective percutaneous coronary intervention: insights from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial.
    White HD; Aylward PE; Gallo R; Bode C; Steg G; Steinhubl SR; Montalescot G;
    Am Heart J; 2010 Jan; 159(1):110-6. PubMed ID: 20102875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
    Chen JL; Chen J; Qiao SB; Guo YL; Wu YJ; Dai J; Yuan JQ; Qin XW; Yang YJ; Gao RL
    Chin Med J (Engl); 2006 Mar; 119(5):355-9. PubMed ID: 16542576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials.
    Dumaine R; Borentain M; Bertel O; Bode C; Gallo R; White HD; Collet JP; Steinhubl SR; Montalescot G
    Arch Intern Med; 2007 Dec; 167(22):2423-30. PubMed ID: 18071163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial.
    Montalescot G; Gallo R; White HD; Cohen M; Steg PG; Aylward PE; Bode C; Chiariello M; King SB; Harrington RA; Desmet WJ; Macaya C; Steinhubl SR;
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1083-91. PubMed ID: 19926048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction.
    Cheng S; Morrow DA; Sloan S; Antman EM; Sabatine MS
    Circulation; 2009 Mar; 119(9):1195-202. PubMed ID: 19237657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test.
    Silvain J; Beygui F; Ankri A; Bellemain-Appaix A; Pena A; Barthelemy O; Cayla G; Gallois V; Galier S; Costagliola D; Collet JP; Montalescot G
    J Am Coll Cardiol; 2010 Feb; 55(7):617-25. PubMed ID: 20170785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel point-of-care assay for the monitoring of low-molecular weight heparins in the cardiac catheterization laboratory.
    Marmur JD; Lakhani M; El Rouby S; Cavusoglu E
    J Invasive Cardiol; 2008 Sep; 20(9):449-54. PubMed ID: 18762674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enoxaparin and percutaneous coronary intervention: a Canadian perspective.
    Fitchett D; Welsh R; Langer A; Goodman S
    Can J Cardiol; 2005 May; 21(6):501-7. PubMed ID: 15917879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Catheter-related thrombosis: biological and clinical evidence for risk with currently available anticoagulants.
    Montalescot G; Walenga JM
    Clin Appl Thromb Hemost; 2009; 15(2):183-96. PubMed ID: 19117960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: results of the STACK-on to ENOXaparin (STACKENOX) study.
    Drouet L; Bal dit Sollier C; Martin J
    Am Heart J; 2009 Aug; 158(2):177-84. PubMed ID: 19619692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated clotting time (ACT)-guided intravenous dalteparin dosing during percutaneous coronary intervention.
    Marmur JD; Poludasu S; Feit A; Battala VR; Cavusoglu E
    J Invasive Cardiol; 2008 Jul; 20(7):323-7. PubMed ID: 18599887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early ambulation and variability in anticoagulation during elective coronary stenting with a single intravenous bolus of low-dose, low-molecular weight heparin enoxaparin.
    Zalc S; Lemos PA; Esteves A; Ribeiro EE; Horta P; Nicolau JC; Ramires JA; Cohen M; Martinez EE
    J Invasive Cardiol; 2006 Feb; 18(2):45-8. PubMed ID: 16446514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.